CDT Equity Flags Sarborg’s Three-Week Patent Filing for Two CF Compounds
Sarborg filed a new Substance of Matter patent covering two established cystic fibrosis compounds using its Signature Agent and Multi-Agent platform in under three weeks. As a 20% shareholder, CDT Equity will collaborate on combination therapy assessments and expand its IP position.
1. Patent Filing Details
Sarborg Limited filed a Substance of Matter patent covering two established cystic fibrosis compounds, achieving submission in under three weeks.
2. Platform Validation
The patent was generated using Sarborg’s proprietary Signature Agent and Multi-Agent platform, powered by its 1,600 Disease and 1,700 Rare Disease databases to rapidly identify therapeutic opportunities.
3. Strategic Implications for CDT
As a 20% shareholder, CDT Equity will work with Sarborg to assess combination therapy prospects, expand its intellectual property portfolio and unlock additional commercial pathways.